カテゴリ： Allied Market Research, 世界, 医療/バイオ

小児用ワクチンのグローバル市場（2021〜2031）：一価、多価

■ 英語タイトル：Global Pediatric Vaccines Market By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines), By Indication (Varicella, Diphtheria, Pertussis and Tetanus, Influenza, Human Papilloma Virus, Measles, Mumps and Rubella, Meningococcal Disease, Pneumococcal Disease, Polio, Rotavirus, Other Indications): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB247）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB247
■ 発行日：2022年11月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：310
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥535,500見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥859,500見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,440,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[小児用ワクチンのグローバル市場（2021〜2031）：一価、多価]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に2,1371.73百万ドルであった世界の小児用ワクチン市場規模が、2031年までに 3,6390.99百万ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）5.4%で成長すると予測しています。本レポートは、小児用ワクチンの世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、種類別（一価、多価）分析、技術別（弱毒生ワクチン、不活化ワクチン、トキソイドワクチン、サブユニット・組換え体・多糖体・コンジュゲートワクチン）分析、適応症別（水痘、髄膜炎菌性疾患、肺炎球菌感染症、ポリオ、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、AstraZeneca Plc.、CSL Limited、Emergent BioSolutions Inc.、GlaxoSmithKline plc.、Johnson & Johnson、Merck & Co., Inc.、Novavax, Inc.、Pfizer Inc.などの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の小児用ワクチン市場規模：種類別
- 一価ワクチンの市場規模
- 多価ワクチンの市場規模
・世界の小児用ワクチン市場規模：技術別
- 弱毒生ワクチンにおける市場規模
- 不活化ワクチンにおける市場規模
- トキソイドワクチンにおける市場規模
- サブユニット・組換え体・多糖体・コンジュゲートワクチンにおける市場規模
・世界の小児用ワクチン市場規模：適応症別
- 水痘における市場規模
- 髄膜炎菌性疾患における市場規模
- 肺炎球菌感染症における市場規模
- ポリオにおける市場規模
- その他における市場規模
・世界の小児用ワクチン市場規模：地域別
- 北米の小児用ワクチン市場規模
- ヨーロッパの小児用ワクチン市場規模
- アジア太平洋の小児用ワクチン市場規模
- 中南米・中東・アフリカの小児用ワクチン市場規模
・企業状況
・企業情報

世界の小児用ワクチン市場は、2021年に21億3,717万ドルと評価され、2022年から2031年にかけて年平均成長率5.4%を記録し、2031年には36億3,909万ドルに達する見込みです。

小児用ワクチンは、小児に獲得免疫をもたらすために投与される生物学的製剤です。ワクチンの投与は、特定の病原体に対する免疫反応を高めるのに役立ちます。小児用ワクチン接種は、さまざまな国で子どもたちの健康を維持する上で重要な役割を担っており、そのため、さまざまな国の疾病予防戦略で使用されています。ウイルス性・細菌性感染症の増加により、ワクチンの需要はここ数年で増加しています。小児用ワクチンは、主にさまざまな年齢の子どもたちに接種され、子どもたちの免疫システムを向上させ、さまざまな感染症に対する防御を保証します。

小児用ワクチン市場は、世界各国で国家予防接種プログラムへの導入が急増していることから、予測期間中に大きな市場成長が見込まれています。また、いくつかの国々で肺炎球菌、インフルエンザ、髄膜炎菌性疾患の有病率が上昇していることがワクチン需要の急増につながり、市場の成長をさらに促進しています。しかし、新ワクチンの承認や複数の製品の回収に関する政府の規制が厳しく、市場成長の妨げになることが予想されます。これとは対照的に、新興市場における需要の増加、新規ワクチン開発のための研究開発活動の増加、医療支出の急増は、小児用ワクチン市場に大きな成長機会をもたらすと予想されます。

小児用ワクチン市場は、種類、技術、疾患、地域によって区分されます。種類別では、市場は一価と多価に二分されます。技術別では、弱毒生ワクチン、不活化ワクチン、トキソイドワクチン、サブユニットワクチン、遺伝子組換えワクチン、多糖体ワクチン、結合型ワクチンに分類されます。疾患別では、水痘、ジフテリア、百日咳・破傷風、インフルエンザ、ヒト乳頭腫ウイルス、麻疹・おたふく風邪・風疹、髄膜炎菌感染症、肺炎球菌感染症、ポリオ、ロタウイルス、その他に分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他の欧州地域）、アジア太平洋地域（日本、中国、オーストラリア、インド、韓国、その他のアジア太平洋地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他のLAMEA地域）に市場を分けて分析しています。

本レポートでは、世界の小児用ワクチン市場で事業を展開する主要企業を包括的に分析しています。主要企業には、Serum Institute of India Pvt. Ltd.、Pfizer、Johnson & Johnson、AstraZeneca plc.、GlaxoSmithKline plc.、Sanofi Aventis、Merck & Co., Inc.、Emergent BioSolutions Inc.、CSL Limited、Novavax, Inc.などがあります。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの世界の小児用ワクチン市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、世界の小児用ワクチンの市場機会を明らかにします。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
・世界の小児用ワクチン市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解します。
・地域別および世界全体の小児用ワクチンの市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
技術別
生ワクチン
不活化ワクチン
トキソイドワクチン
サブユニット・組み換え・多糖類・結合型ワクチン

種類別
一価
多価

疾患別
水痘
はしか・おたふくかぜ・風疹
髄膜炎菌感染症
肺炎球菌感染症
ポリオ
ロタウイルス
ジフテリア・百日咳・破傷風
インフルエンザ
ヒト乳頭腫ウイルス
その他

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
中国
日本
インド
オーストラリア
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
AstraZeneca Plc.
CSL Limited
Emergent BioSolutions Inc.
GlaxoSmithKline plc.
Johnson & Johnson
Merck & Co., Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi Aventis
Serum Institute of India Pvt. Ltd.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Monovalent
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Multivalent
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
CHAPTER 5: GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY
5.1 Overview
5.1.1 Market size and forecast
5.2 Live Attenuated Vaccines
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Inactivated Vaccines
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
5.4 Toxoid Vaccines
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market share analysis by country
5.5 Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market share analysis by country
CHAPTER 6: GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Varicella
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Diphtheria, Pertussis and Tetanus
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Influenza
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
6.5 Human Papilloma Virus
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market share analysis by country
6.6 Measles, Mumps and Rubella
6.6.1 Key market trends, growth factors and opportunities
6.6.2 Market size and forecast, by region
6.6.3 Market share analysis by country
6.7 Meningococcal Disease
6.7.1 Key market trends, growth factors and opportunities
6.7.2 Market size and forecast, by region
6.7.3 Market share analysis by country
6.8 Pneumococcal Disease
6.8.1 Key market trends, growth factors and opportunities
6.8.2 Market size and forecast, by region
6.8.3 Market share analysis by country
6.9 Polio
6.9.1 Key market trends, growth factors and opportunities
6.9.2 Market size and forecast, by region
6.9.3 Market share analysis by country
7.0 Rotavirus
7.0.1 Key market trends, growth factors and opportunities
7.0.2 Market size and forecast, by region
7.0.3 Market share analysis by country
7.1 Other Indications
7.1.1 Key market trends, growth factors and opportunities
7.1.2 Market size and forecast, by region
7.1.3 Market share analysis by country
CHAPTER 7: GLOBAL PEDIATRIC VACCINES MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Technology
7.2.4 North America Market size and forecast, by Indication
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Technology
7.2.5.1.4 Market size and forecast, by Indication
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Technology
7.2.5.2.4 Market size and forecast, by Indication
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Technology
7.2.5.3.4 Market size and forecast, by Indication
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Technology
7.3.4 Europe Market size and forecast, by Indication
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Technology
7.3.5.1.4 Market size and forecast, by Indication
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Technology
7.3.5.2.4 Market size and forecast, by Indication
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Technology
7.3.5.3.4 Market size and forecast, by Indication
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Technology
7.3.5.4.4 Market size and forecast, by Indication
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Technology
7.3.5.5.4 Market size and forecast, by Indication
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Technology
7.3.5.6.4 Market size and forecast, by Indication
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Technology
7.4.4 Asia-Pacific Market size and forecast, by Indication
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Technology
7.4.5.1.4 Market size and forecast, by Indication
7.4.5.2 Japan
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Technology
7.4.5.2.4 Market size and forecast, by Indication
7.4.5.3 India
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Technology
7.4.5.3.4 Market size and forecast, by Indication
7.4.5.4 Australia
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Technology
7.4.5.4.4 Market size and forecast, by Indication
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Technology
7.4.5.5.4 Market size and forecast, by Indication
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Technology
7.4.5.6.4 Market size and forecast, by Indication
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Technology
7.5.4 LAMEA Market size and forecast, by Indication
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Technology
7.5.5.1.4 Market size and forecast, by Indication
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Technology
7.5.5.2.4 Market size and forecast, by Indication
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Technology
7.5.5.3.4 Market size and forecast, by Indication
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Technology
7.5.5.4.4 Market size and forecast, by Indication
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 AstraZeneca Plc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 CSL Limited
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Emergent BioSolutions Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 GlaxoSmithKline plc.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Johnson & Johnson
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Merck & Co., Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Novavax, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Pfizer Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sanofi Aventis
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Serum Institute of India Pvt. Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 2. GLOBAL PEDIATRIC VACCINES MARKET FOR MONOVALENT, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. GLOBAL PEDIATRIC VACCINES MARKET FOR MONOVALENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. GLOBAL PEDIATRIC VACCINES MARKET FOR MULTIVALENT, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. GLOBAL PEDIATRIC VACCINES MARKET FOR MULTIVALENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 6. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 7. GLOBAL PEDIATRIC VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 8. GLOBAL PEDIATRIC VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 9. GLOBAL PEDIATRIC VACCINES MARKET FOR INACTIVATED VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. GLOBAL PEDIATRIC VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 11. GLOBAL PEDIATRIC VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. GLOBAL PEDIATRIC VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 13. GLOBAL PEDIATRIC VACCINES MARKET FOR SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. GLOBAL PEDIATRIC VACCINES MARKET FOR SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 15. GLOBAL GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. GLOBAL PEDIATRIC VACCINES MARKET FOR VARICELLA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 17. GLOBAL PEDIATRIC VACCINES MARKET FOR VARICELLA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 18. GLOBAL PEDIATRIC VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS AND TETANUS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 19. GLOBAL PEDIATRIC VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS AND TETANUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 20. GLOBAL PEDIATRIC VACCINES MARKET FOR INFLUENZA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 21. GLOBAL PEDIATRIC VACCINES MARKET FOR INFLUENZA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 22. GLOBAL PEDIATRIC VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 23. GLOBAL PEDIATRIC VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 24. GLOBAL PEDIATRIC VACCINES MARKET FOR MEASLES, MUMPS AND RUBELLA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 25. GLOBAL PEDIATRIC VACCINES MARKET FOR MEASLES, MUMPS AND RUBELLA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 26. GLOBAL PEDIATRIC VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 27. GLOBAL PEDIATRIC VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 28. GLOBAL PEDIATRIC VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 29. GLOBAL PEDIATRIC VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 30. GLOBAL PEDIATRIC VACCINES MARKET FOR POLIO, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 31. GLOBAL PEDIATRIC VACCINES MARKET FOR POLIO, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 32. GLOBAL PEDIATRIC VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 33. GLOBAL PEDIATRIC VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 34. GLOBAL PEDIATRIC VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 35. GLOBAL PEDIATRIC VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 36. GLOBAL PEDIATRIC VACCINES MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 37. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 38. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 39. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 40. NORTH AMERICA GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 41. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 42. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 43. U.S. GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 44. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 45. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 46. CANADA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 47. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 48. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 49. MEXICO GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 50. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 51. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 52. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 53. EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 54. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 55. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 56. GERMANY GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 57. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 58. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 59. FRANCE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 60. UK GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 61. UK GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 62. UK GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 63. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 64. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 65. ITALY GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 66. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 67. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 68. SPAIN GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 69. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 70. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 71. REST OF EUROPE GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 72. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 73. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 74. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 75. ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 76. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 77. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 78. CHINA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 79. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 80. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 81. JAPAN GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 82. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 83. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 84. INDIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 85. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 86. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 87. AUSTRALIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 88. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 89. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 90. SOUTH KOREA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 91. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 92. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 93. REST OF ASIA-PACIFIC GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 94. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 95. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 96. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 97. LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 98. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 99. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 100. BRAZIL GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 101. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 102. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 103. SAUDI ARABIA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 104. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 105. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 106. SOUTH AFRICA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 107. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 108. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)
TABLE 109. REST OF LAMEA GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 110.ASTRAZENECA PLC.: COMPANY SNAPSHOT
TABLE 111.ASTRAZENECA PLC.: OPERATING SEGMENTS
TABLE 112.ASTRAZENECA PLC.: PRODUCT PORTFOLIO
TABLE 113.ASTRAZENECA PLC.: NET SALES
TABLE 114.ASTRAZENECA PLC.: KEY STRATERGIES
TABLE 115.CSL LIMITED: COMPANY SNAPSHOT
TABLE 116.CSL LIMITED: OPERATING SEGMENTS
TABLE 117.CSL LIMITED: PRODUCT PORTFOLIO
TABLE 118.CSL LIMITED: NET SALES
TABLE 119.CSL LIMITED: KEY STRATERGIES
TABLE 120.EMERGENT BIOSOLUTIONS INC.: COMPANY SNAPSHOT
TABLE 121.EMERGENT BIOSOLUTIONS INC.: OPERATING SEGMENTS
TABLE 122.EMERGENT BIOSOLUTIONS INC.: PRODUCT PORTFOLIO
TABLE 123.EMERGENT BIOSOLUTIONS INC.: NET SALES
TABLE 124.EMERGENT BIOSOLUTIONS INC.: KEY STRATERGIES
TABLE 125.GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 126.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
TABLE 127.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 128.GLAXOSMITHKLINE PLC.: NET SALES
TABLE 129.GLAXOSMITHKLINE PLC.: KEY STRATERGIES
TABLE 130.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 131.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 132.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 133.JOHNSON & JOHNSON: NET SALES
TABLE 134.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 135.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 136.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 137.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 138.MERCK & CO., INC.: NET SALES
TABLE 139.MERCK & CO., INC.: KEY STRATERGIES
TABLE 140.NOVAVAX, INC.: COMPANY SNAPSHOT
TABLE 141.NOVAVAX, INC.: OPERATING SEGMENTS
TABLE 142.NOVAVAX, INC.: PRODUCT PORTFOLIO
TABLE 143.NOVAVAX, INC.: NET SALES
TABLE 144.NOVAVAX, INC.: KEY STRATERGIES
TABLE 145.PFIZER INC.: COMPANY SNAPSHOT
TABLE 146.PFIZER INC.: OPERATING SEGMENTS
TABLE 147.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 148.PFIZER INC.: NET SALES
TABLE 149.PFIZER INC.: KEY STRATERGIES
TABLE 150.SANOFI AVENTIS: COMPANY SNAPSHOT
TABLE 151.SANOFI AVENTIS: OPERATING SEGMENTS
TABLE 152.SANOFI AVENTIS: PRODUCT PORTFOLIO
TABLE 153.SANOFI AVENTIS: NET SALES
TABLE 154.SANOFI AVENTIS: KEY STRATERGIES
TABLE 155.SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
TABLE 156.SERUM INSTITUTE OF INDIA PVT. LTD.: OPERATING SEGMENTS
TABLE 157.SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
TABLE 158.SERUM INSTITUTE OF INDIA PVT. LTD.: NET SALES
TABLE 159.SERUM INSTITUTE OF INDIA PVT. LTD.: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 組換えワクチンのグローバル市場（2021〜2031）：ヒトパピローマウイルス、髄膜炎菌、その他
  • 皮膚生検のグローバル市場（2021～2031）：薄片生検、パンチ生検、切除生検
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB247 )"小児用ワクチンのグローバル市場（2021〜2031）：一価、多価" (英文：Global Pediatric Vaccines Market By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines), By Indication (Varicella, Diphtheria, Pertussis and Tetanus, Influenza, Human Papilloma Virus, Measles, Mumps and Rubella, Meningococcal Disease, Pneumococcal Disease, Polio, Rotavirus, Other Indications): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。